scispace - formally typeset
G

Gary A. Silverman

Researcher at Washington University in St. Louis

Publications -  139
Citations -  13136

Gary A. Silverman is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Serpin & Gene. The author has an hindex of 41, co-authored 131 publications receiving 12186 citations. Previous affiliations of Gary A. Silverman include University of Pittsburgh & Washington & Jefferson College.

Papers
More filters
Journal ArticleDOI

Human Macrophage Metalloelastase. GENOMIC ORGANIZATION, CHROMOSOMAL LOCATION, GENE LINKAGE, AND TISSUE-SPECIFIC EXPRESSION

TL;DR: Human macrophage metalloelastase (HME) is a recent addition to the matrix metalloproteinase (MMP) family that was initially found to be expressed in alveolar macrophages of cigarette smokers and analysis of the structure and location of the gene was performed to understand more about HME expression.
Journal ArticleDOI

Co-expression of the Squamous Cell Carcinoma Antigens 1 and 2 in Normal Adult Human Tissues and Squamous Cell Carcinomas

TL;DR: Examination of squamous cell carcinomas of the lung and head and neck showed that S CCA1 and SCCA2 were co-expressed in moderately and well-differentiated tumors and indicated that these serpins may coordinately regulate cysteine and serine proteinase activity in both normal and transformed tissues.
Journal ArticleDOI

Serpins flex their muscle: I. Putting the clamps on proteolysis in diverse biological systems.

TL;DR: Serpins compose the largest superfamily of peptidase inhibitors and are well known as regulators of hemostasis and thrombolysis and are emerging as important elements within a diversity of biological systems by serving as chaperones, hormone transporters, or anti-angiogenic factors.
Journal ArticleDOI

Modeling molecular and cellular aspects of human disease using the nematode Caenorhabditis elegans.

TL;DR: The ability to process large numbers of isogenic animals through automated work stations suggests that C. elegans, manifesting different aspects of human disease phenotypes, will become the platform of choice for in vivo drug discovery and target validation using high-throughput/content screening technologies.